Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Magrolimab (Hu5F9-G4) in Relapsed/Refractory AML
NCT03922477Phase 1Terminated
- Sponsor
- Roche
- Start
- Oct 2019
- Primary completion
- Nov 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab and magrolimab in acute myeloid leukemia (AML), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events up to 13 months, Complete Remission up to 3 months and 1 more. Started Oct 2019; status: terminated.
02
Drugs
atezolizumabmagrolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03922477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922477.